KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) R&D In Process (2021 - 2025)

Regeneron Pharmaceuticals has reported R&D In Process over the past 5 years, most recently at $18.7 million for Q4 2025.

  • Quarterly results put R&D In Process at $18.7 million for Q4 2025, up 35.51% from a year ago — trailing twelve months through Dec 2025 was $124.1 million (up 22.87% YoY), and the annual figure for FY2025 was $124.1 million, up 22.87%.
  • R&D In Process for Q4 2025 was $18.7 million at Regeneron Pharmaceuticals, down from $83.1 million in the prior quarter.
  • Over the last five years, R&D In Process for REGN hit a ceiling of $197.0 million in Q2 2022 and a floor of $7.1 million in Q1 2024.
  • Median R&D In Process over the past 5 years was $30.0 million (2022), compared with a mean of $47.6 million.
  • Biggest five-year swings in R&D In Process: surged 99.64% in 2023 and later crashed 87.34% in 2024.
  • Regeneron Pharmaceuticals' R&D In Process stood at $48.0 million in 2021, then plummeted by 37.5% to $30.0 million in 2022, then changed by 0.0% to $30.0 million in 2023, then plummeted by 54.0% to $13.8 million in 2024, then surged by 35.51% to $18.7 million in 2025.
  • The last three reported values for R&D In Process were $18.7 million (Q4 2025), $83.1 million (Q3 2025), and $10.0 million (Q2 2025) per Business Quant data.